吉西他滨联合奥沙利铂经肝动脉化疗栓塞治疗肝癌临床疗效的Meta分析

Efficacy and Adverse Reactions of Gemcitabine and Oxaliplatin in Transcatheter Arterial Chemoembolization for Patients with Hepatocellular Carcinoma:a Meta-analysis

目的运用循证医学方法对吉西他滨联合奥沙利铂经肝动脉化疗栓塞治疗肝癌的临床疗效进行系统评价.方法：计算机检索中文科技期刊数据库、万方数据资源系统、中国期刊全文数据库、中国生物医学文献服务系统,在评价文献质量的基础上纳入了符合标准的随机对照临床试验4项,对其进行异质性分析,然后采用固定效应模型合并疾病控制率、1年生存率、毒副反应（白细胞和血小板减少）发生率,进行Meta分析.结果：吉西他滨联合奥沙利铂经肝动脉化疗栓塞治疗肝癌的疾病控制率（OR=3.40;95% CI：2.14～5.39）和1年生存期（OR=2.78;95% CI：1.83～4.21）与对照组比较差异均有统计学意义.结论：吉西他滨联合奥沙利铂经肝动脉化疗栓塞治疗肝癌可提高疾病控制率和1年生存期.

Objective: To assess the efficacy and adverse reactions of gemcitabine and oxaliplatin in transcatheter arterial chemoembolization for patients with hepatocellular carcinoma by evidence-based medicine methods.Methods: The References were retrieved from Wanfang Data, VIP information, CNKI and Sinomed. After strict quality evaluation of the articles, 4 clinical randomized controlled trials were internalized according to our accepting criteria. The heterogeneity test among the 4 trials were did, and then the disease control rate, 1-year survival rate and th rates of adverse reactions were consolidated based on fixed effects model for Meta-analysis.Results: The disease control rate (OR=3.40;95% CI:2.14~5.39) and 1-year survival rate (OR=2.78;95% CI:1.83~4.21) of gemcitabine and oxaliplatin in transcatheter arterial chemoembolization for patients with gemcitabine and oxaliplatin were significantly different from those of control group.Conclusion: Gemcitabine and oxaliplatin have positive effect in transcatheter arterial chemoembolization for patients with hepatocellular carcinoma by improving the disease control rate and 1-year survival rate.